The FDA announced a “Rare Disease Framework Initiative” aimed at reimagining how it regulates therapies for rare diseases, shifting from a one-size-fits-all approach to condition-specific standards. The agency plans to solicit input from patients and experts and produce a “fit-for-purpose framework” covering steps from preclinical engagement through post-marketing requirements. The announcement extends the agency’s broader “reset” under which it has signaled reversal of some earlier rare-disease policy decisions that drew criticism from industry and patient advocates. Analysts noted the agency is not lowering evidentiary bars, but may reduce uncertainty in how sponsors navigate to approval. A feedback meeting is scheduled for Oct. 28, and officials have signaled an expected timeline for initial recommendations around February, according to reporting referenced in the update. For biotech developers, the initiative’s practical impact will depend on how it changes expectations around endpoints, evidence generation plans, and post-approval obligations for small patient populations.